• GBS Banner Sept 2014
  • GBS Banner 2

Next Generation Sequencing is delivering on its promise as a life sciences research tool.  Yet the adoption of NGS technology in the clinical laboratory is in its infancy.  It is believed that it holds immense promise for patient care, enabling personalized intervention to prevent and treat disease, but the full clinical and economic value of NGS is only just beginning to be understood.  Clinicians are now beginning to demand and adopt this powerful tool to guide treatment decision-making.  Assessing this emerging value is complex - while NGS offers the potential to transform clinical care, the technology will likely alter the economics of medicine, disrupting established stakeholder business models.

This symposium offers an opportunity to learn and engage on the early real-world clinical applications of NGS in the oncology space. It will involve a review of the clinical and health economic value perspectives of providers, payers, and technology innovators, and examine how the technology may fit with emerging oncology payment/business model approaches. The symposium will gather a range of clinical and economic stakeholders in advanced genomics, and creates a participatory forum for dialogue on how to define the value of NGS, and determine the evidence required to support and incorporate it in the on-going delivery of patient care.

Stakeholders participating this forum include:  

  • Treating Clinicians and Hospital Providers
  • Clinical Laboratory Providers
  • Government and Commercial Payers
  • Targeted Therapy Innovators
  • Diagnostic Content and Platform Innovators
  • Genomic Research Institutions

View agenda at a glance  

Distinguished Speaker Faculty Includes 

Robert E Baird

Robert E. Baird, Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network

Paul R. Billings, M.D., Ph.D., Chief Medical Officer (consulting), Thermo Fisher Scientific

Douglas B. Johnson

Douglas B. Johnson, M.D., M.S.C.I., Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center

Michael Kolodziej

Michael Kolodziej, M.D., National Medical Director, Oncology Strategy, Aetna

Shashikant Kulkarni

Shashikant Kulkarni, Ph.D., FACMG, Director, Cytogenomics and Molecular Pathology Program Director, Clinical Genomics Fellowship Program; Associate Professor, Pathology & Immunology, Pediatrics and Genetics, Washington University School of Medicine

Pan_Jonathan

Jonathan Pan, Director, Oncology Companion Diagnostics and Disease Strategy, GlaxoSmithKline

Additional speakers to be announced.